Lucy L Gibson
Overview
Explore the profile of Lucy L Gibson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abdelnour C, Gibson L, Batzu L, Aarsland D
J Parkinsons Dis
. 2025 Feb;
:1877718X251315645.
PMID: 39973493
Cognitive impairment is a common non-motor symptom in people with Parkinson's disease (PD) and is associated to poor clinical outcomes. Currently, rivastigmine is the only approved medication for PD dementia,...
2.
Gibson L, Gonzalez M, Ashton N, Tovar-Rios D, Blanc F, Pilotto A, et al.
Alzheimers Dement
. 2024 Dec;
21(2):e14434.
PMID: 39732510
Introduction: Neuropsychiatric symptoms (NPSs) are common in dementia with Lewy bodies (DLB) but their neurobiological mechanisms are poorly understood. Methods: NPSs and cognition were assessed annually in participants (DLB n ...
3.
Gibson L, Mueller C, Stewart R, Aarsland D
Psychol Med
. 2024 Sep;
:1-10.
PMID: 39324394
Background: Very late-onset psychosis (VLOP) is associated with higher rates of dementia but the proportion who develop dementia with Lewy bodies (DLB) is unknown. We aimed to identify individuals with...
4.
Gibson L, Weintraub D, Lemmen R, Perera G, Chaudhuri K, Svenningsson P, et al.
Mov Disord
. 2024 Jul;
39(10):1697-1709.
PMID: 39036849
Estimates of the risk of dementia in Parkinson's disease (PDD) vary widely. We aimed to review the incidence of PDD and in a meta-analysis estimate the pooled annual incidence and...
5.
Gibson L, Abdelnour C, Chong J, Ballard C, Aarsland D
Curr Opin Neurol
. 2023 Jun;
36(4):264-275.
PMID: 37387459
Purpose Of Review: Currently, no disease modifying therapies (DMTs) have been approved for use in dementia with Lewy bodies (DLB). Clinical trials face difficulties due to the clinical and neuropathological...
6.
Abdelnour C, Gonzalez M, Gibson L, Poston K, Ballard C, Cummings J, et al.
Neurol Ther
. 2023 Apr;
12(3):727-749.
PMID: 37017910
Introduction: Reviews of randomized clinical trials (RCTs) in dementia with Lewy bodies (DLB) are essential for informing ongoing research efforts of symptomatic therapies and potentially disease-modifying therapies (DMTs). Methods: We...
7.
Gibson L, Pollak T, Hart M, Heslegrave A, Hye A, Church A, et al.
J Neuropsychiatry Clin Neurosci
. 2023 Jan;
35(3):236-243.
PMID: 36710627
Objective: -methyl-d-aspartate receptor (NMDAR) encephalitis is an autoantibody-mediated neurological syndrome with prominent cognitive and neuropsychiatric symptoms. The clinical relevance of NMDAR antibodies outside the context of encephalitis was assessed in...
8.
Gibson L, Aarsland D, Suemoto C
Aging (Albany NY)
. 2022 Dec;
14(23):9384-9385.
PMID: 36495589
No abstract available.
9.
Batzu L, Rota S, Hye A, Heslegrave A, Trivedi D, Gibson L, et al.
NPJ Parkinsons Dis
. 2022 Nov;
8(1):154.
PMID: 36371469
Early identification of cognitive impairment in Parkinson's disease (PD) has important clinical and research implications. The aim of our study was to investigate the role of plasma tau phosphorylated at...
10.
Gibson L, Grinberg L, Ffytche D, Leite R, Rodriguez R, Ferretti-Rebustini R, et al.
Alzheimers Dement
. 2022 Sep;
19(4):1372-1382.
PMID: 36150075
Introduction: Neuropsychiatric symptoms (NPS) are common in Lewy body disease (LBD), but their etiology is poorly understood. Methods: In a population-based post mortem study neuropathological data was collected for Lewy...